Scinai Immunotherapeutics Ltd. reports developments as a Nasdaq-listed biopharmaceutical issuer with American Depositary Shares and a dual model spanning inflammation and immunology R&D and contract development and manufacturing services. Its updates cover the PC111 monoclonal antibody program targeting soluble Fas Ligand for severe dermatological and autoimmune conditions, next-generation NanoAb-based programs, and development rights or research funding tied to its immunology pipeline.
Company news also covers the CDMO platform operated through Scinai Biopharma Services Ltd., including the completed acquisition of Recipharm Israel, manufacturing capabilities across biologics and small-molecule programs, customer service expansion, operating results, material agreements, shareholder matters, capital-structure disclosures, and Nasdaq listing compliance for its ADSs.
Scinai Immunotherapeutics (NASDAQ: SCNI) reported nine-month revenue growth of 167% as its contract development and manufacturing business expanded. Revenue reached $2.805 million, versus $1.049 million a year earlier, including the acquired Yavne operations. Operating loss widened to $6.563 million from $5.637 million. Net loss narrowed to $393,000 from $6.244 million, primarily reflecting a $6.401 million noncash acquisition gain.
An expanded U.S. customer agreement carries approximately $5.1 million in committed base services, subject to performance and contractual terms. Committed Customer Orders reached approximately $8.32 million; this measure is neither revenue nor remaining backlog. October financing raised approximately $5.3 million net. Scinai expects cash and anticipated customer payments to support operations to late 2027, dependent on execution and collections. Additional manufacturing work remains uncommitted.
Scinai Immunotherapeutics (NASDAQ: SCNI) updated shareholders on its contract development and manufacturing business and financing that raised approximately $5.3 million net. Management estimates runway to late 2027, potentially extending into the third quarter of 2028 if later project phases are activated and delivered; both estimates depend on sales, timely collections and execution.
A U.S.-based customer's agreement includes approximately $5.1 million in committed base service fees, subject to performance and contractual terms. Committed Customer Orders reached approximately $8.1 million on October 20, 2026, versus $1.9 million at year-end 2025; this measure is not revenue or remaining backlog. Additional services with an indicative value of approximately $5.85 million remain uncommitted. Clinical manufacturing is planned for January 2027. The financing included equity issuance and cash exercises of existing warrants, with dilution for shareholders.
Scinai Immunotherapeutics (NASDAQ: SCNI) closed a private placement and warrant inducement transaction, receiving approximately $4.0 million in aggregate gross proceeds. The placement included 2,458,334 American Depositary Shares (ADSs), or pre-funded warrants in their place, plus warrants for up to 3,687,501 ADSs. Existing warrants for up to 879,194 ADSs were exercised at a reduced price of $1.20 per ADS, with additional warrants issued for up to 1,318,791 ADSs.
Scinai estimates an operating runway to late 2027 based on its operating plan, cash resources, financing proceeds and expected customer collections and sales. Activation of later customer-program phases and associated receipts, after delivery costs, could extend runway into 2028. Both estimates depend on sales, collections, timely payments and execution, and remain subject to customer termination rights and changes in plans and costs.
Scinai Immunotherapeutics (NASDAQ: SCNI) entered financing agreements with an existing institutional investor expected to raise approximately $4.0 million gross. The private placement covers 2,458,334 American Depositary Shares (ADSs), or pre-funded warrants, at $1.20 per ADS with accompanying warrants. It includes Series A-1 warrants for up to 3,687,501 ADSs. The investor also agreed to exercise existing warrants for 879,194 ADSs at a reduced $1.20 exercise price, receiving new warrants for up to 1,318,791 ADSs.
Both Series A-1 warrant groups are immediately exercisable at $1.20 per ADS for five years. Closing is expected on or about October 15, 2026, subject to customary conditions. Gross proceeds exclude future new-warrant exercises and precede placement-agent fees and expenses. Scinai plans to use net proceeds with existing cash to expand its contract development and manufacturing platform, advance customer programs and selectively invest in immunotherapy.
Scinai Immunotherapeutics (SCNI) signed a development and clinical manufacturing agreement through its subsidiary with approximately $5.1 million in committed base service fees. The U.S.-based, Nasdaq-listed customer is expanding an existing engagement for an investigational oncology product. Fees are subject to performance and contractual termination rights. Scinai expects revenue contributions in 2026 and 2027, with clinical manufacturing planned to begin in January 2027 and stability services continuing beyond 2027.
Committed Customer Orders reached approximately $7.6 million, up approximately 300% from $1.9 million at year-end 2025 and more than double August 16, 2026 levels. Potential additional manufacturing carries an indicative, uncommitted $5.85 million service-fee value for late 2027 through the first half of 2028, subject to scope, pricing, authorization, capacity and customer progress.
Scinai Immunotherapeutics (SCNI) has regained compliance with Nasdaq Listing Rule 5550(a)(2) regarding the $1.00 minimum bid price requirement.
Nasdaq notified the company on September 21, 2026 that the minimum bid price matter is closed after Scinai’s ADSs posted a closing bid of at least $1.00 per share for 19 consecutive business days from August 21 through September 17, 2026. The earlier deficiency arose when the ADSs traded below $1.00 for 30 consecutive business days prior to a March 12, 2026 notice from Nasdaq Staff.
Scinai Immunotherapeutics (SCNI) ended its PC111 option and license arrangements with PinCell as of August 31, 2026 and is refocusing capital on its NanoAb platform and CDMO business.
No new negative scientific findings drove the decision; Scinai cites the absence of secured grant funding for PC111 and the capital required to de‑risk a preclinical asset. R&D efforts will center on the NanoAb platform under the long-term collaboration with the Max Planck Society and University Medical Center Göttingen, including an intradermal IL‑17 psoriasis program tied to an approximately €12 million FENG grant application and a systemic IL‑17 bispecific validation program.
On the CDMO side, Committed Customer Orders totaled about $3.1 million as of August 16, 2026. The company is pursuing around $5 million of CDMO revenue for 2026 and has begun expanded CMC activities for a U.S. biopharma customer under an existing contract while negotiating a broader definitive agreement.
Scinai Immunotherapeutics (NASDAQ: SCNI) reported first half 2026 results and CDMO business progress. Revenues for the six months ended June 30, 2026 rose to $949 thousand from $773 thousand, driven mainly by the acquired Yavne CDMO operations, while cost of revenues increased to $3.3 million, resulting in a gross loss of $2.4 million.
Operating loss widened to $4.6 million, but net income reached $1.6 million versus a $4.1 million loss a year earlier, primarily due to a $6.4 million bargain purchase gain from the Recipharm Israel acquisition. Cash, cash equivalents and restricted cash totaled about $2.9 million, and shareholders’ equity was $11.7 million. Committed CDMO customer orders were approximately $3.1 million as of August 16, 2026, with roughly $2.1 million invoiced, and about $650 thousand received for an expanded U.S. clinical manufacturing program. Scinai will host an investor webinar on August 26, 2026 at 11:00 a.m. EDT.
Scinai Immunotherapeutics (NASDAQ: SCNI) announced that its CDMO subsidiary, Scinai Biopharma Services, has appointed Eran Kuratz as Head of Supply Chain and Business Process Administration, reporting to CEO Amir Reichman. Kuratz brings over 30 years of leadership in supply chain and operations across pharmaceutical, biotechnology, medical-device and industrial companies, including senior roles at Kamada, Gamida Cell, OdysightAI, Elite PepsiCo-Frito-Lay and EnvyHer.
In his new role, he oversees supply chain and operational support functions such as procurement and contracting, warehousing, logistics, inventory management, budgeting and cost control, bookkeeping administration, and IT and business systems, including ERP, CRM, quality-management platforms and cybersecurity. According to the company, this appointment supports integration and scale-up following the first-quarter 2026 acquisition of Recipharm Israel, which added a Yavne site complementing the Jerusalem biologics facility and expanded Scinai’s CDMO capacity and technical capabilities.
Scinai (NASDAQ:SCNI) reported Q1 2026 revenue of $489 thousand versus $586 thousand in Q1 2025, with $200 thousand from the newly acquired Yavne CDMO site. Operating loss was $2.5 million, while net income reached $3.6 million driven by a $6.2 million bargain purchase gain.
Scinai completed the Recipharm Israel acquisition, adding a second manufacturing site and $6.2 million of net identifiable assets, and is advancing non-dilutive grant applications to support the PC111 antibody and IL-17 bispecific NanoAb programs and CDMO expansion.